Pancreatic cancer is the definition of an unmet need. Five-year survival sits around 13%. Most patients are diagnosed too late for surgery. And the chemotherapy options, while improving, remain brutal.
Sonire Therapeutics wants to burn the tumor out. Without opening the patient up. Without putting them under anesthesia. In about 20 minutes.
The company closed an $18 million Series A led by Santé Ventures, with participation from Japanese institutional investors including Fast Track Initiative, Nomura SPARX Investment, and SBI Investment. The money funds what Sonire says is the first randomized clinical trial of High-Intensity Focused Ultrasound (HIFU) in pancreatic cancer.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
The device, codenamed Suizenji, focuses ultrasound waves from outside the body onto a single point inside, heating and destroying cancer cells through thermal ablation. Real-time imaging guidance and robotic positioning keep the energy targeted. The FDA already granted it Breakthrough Device Designation for pancreatic cancer.
HIFU has existed for years in other indications, but pancreatic tumors have been tough because of the organ’s position deep in the abdomen, surrounded by critical structures. If Sonire can show efficacy in a randomized setting, that’s a meaningful shift in how we approach unresectable pancreatic disease.
The Japanese investor syndicate is notable too. Multiple institutions from Japan participating in a U.S. device company’s Series A suggests cross-border commercialization interest, even if no distribution deals have been announced.
For context, Actuate Therapeutics recently published data showing a 40% survival gain in pancreatic cancer with a small molecule approach. The field is moving. Sonire is betting that the path forward involves physics, not chemistry.
